カテゴリー： 世界, 医療/バイオ, Allied Market Research

世界の胃がん市場2021年-2031年：疾患種類別（腺がん、リンパ腫、消化管間質腫瘍、カルチノイド腫瘍、その他）、治療種類別（免疫療法、標的療法、化学療法、放射線療法＆外科）、薬剤クラス別（PD-1/PD-L1阻害剤、HER2アンタゴニスト、VEGFR2アンタゴニスト、その他）、投与経路別（経口、注射剤）、流通チャネル別（病院薬局、専門薬局＆小売薬局、その他）

【英語タイトル】Gastric Cancer Market By Disease Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others), By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery), By Drug Class Outlook (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Specialty and Retail Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Allied Market Researchが出版した調査資料（ALD23SEP129）・商品コード：ALD23SEP129
・発行会社（調査会社）：Allied Market Research
・発行日：2023年4月
・ページ数：350
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：生命科学
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥528,360見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥848,040見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,420,800見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

世界の胃がん市場は、2021年の21億ドルから2031年には107億ドルに達すると予測され、2022年から2031年までの年平均成長率は17.9%です。胃がんは、胃の粘膜に悪性（がん）細胞ができる病気です。年齢、食生活、座りがちな生活習慣などが胃がん発症のリスクにつながります。胃がんの症状には、消化不良や胃の不快感や痛みなどがあります。胃がんの診断には、胃や食道を調べる検査が用いられます。

胃がん患者数の増加に伴い、胃がん市場の拡大が期待されます。胃がんの原因は、肥満の増加、高度に加工された食品、甘い飲料の摂取の増加、喫煙、遺伝子の遺伝子組み換え、がんの家族歴、アルコールの摂取などの付加的な危険因子により著しく増加しています。さらに、胃がんの罹患率の上昇は今後も続くと予想され、この傾向は効率的な治療法の需要を押し上げています。これらすべての要因が、予測期間中の市場収益の成長を促進すると予測されています。

胃がん治療は、手術、放射線療法、診断、病期分類など、実施しなければならない検査が数多くあるため、高額になる可能性があります。胃がんの診断や病期分類には、画像検査、内視鏡検査、生検、血液検査など、さまざまな検査や処置が頻繁に必要です。これらの検査には高額な費用がかかり、複数回の受診が必要になることもあります。胃がんの治療費は高額であるため、市場は大きな制約を受けると予測されます。

胃がん市場は、医療意識の高まりにより恩恵を受けると予測されます。胃がんに関連する危険因子に対する認識が高まるにつれて、医療機関を受診したり検診を受けたりする傾向が高まります。胃がんに対する認識が高まることで、より多くの症例がより早い段階で発見されるようになります。胃がんの早期発見は、効果的な治療と患者さんの予後の改善に不可欠です。そのため、胃がん患者には薬物療法、手術療法、放射線療法などの診断・治療オプションが必要になることがあります。これらの要因は、市場で事業を展開する主要企業にとって、いくつかの成長機会を生み出すと期待されています。

COVID-19の大流行は、胃がんの治療、特にスクリーニング、診断、治療のタイミングに悪影響を及ぼしました。COVID-19は、ほとんどすべての産業に影響を及ぼした前例のない世界的な公衆衛生上の緊急事態であり、その長期的な影響は、大流行後の期間にさまざまな最終用途産業の成長に反映されると予測されています。 多くの胃がん患者がパンデミックによる治療の中断を経験しています。COVID-19の感染リスクを減らすために、治療スケジュールを変更しなければならず、その結果、一部の患者の治療計画が遅れたり変更されたりしました。医療現場でのCOVID-19曝露に対する懸念から、患者は治療を受けることをためらいました。胃癌の臨床試験はパンデミックの影響を大きく受け、多くの臨床試験が延期または遅延しました。
本レポートで紹介する主な企業は、Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis and Bristol Myers Squibb Companyなどです。

ステークホルダーにとっての主なメリット
2021年から2031年までの胃がん市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、胃がん市場の有力な機会を特定します。
主な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
胃がん市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別および世界別の胃がん市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
疾患タイプ別
腺がん
リンパ腫
消化管間質腫瘍
カルチノイド腫瘍
その他

治療タイプ別
免疫療法
標的療法
化学療法
放射線療法・手術療法

薬剤クラス別展望
PD-1/PD-L1 阻害薬
HER2拮抗薬
VEGFR2拮抗薬
その他

投与経路別
経口剤
注射剤

流通チャネル別
専門薬局・小売薬局
その他
病院薬局

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
イギリス
フランス
スペイン
イタリア
その他のヨーロッパ
アジア太平洋
中国
日本
インド
韓国
オーストラリア
その他のアジア太平洋地域
LAMEA
ブラジル
アラブ首長国連邦
サウジアラビア
南アフリカ
その他の地域

主要市場プレイヤー
○ Novartis AG
○ Pfizer, Inc.
○ Mylan N.V.
○ F. Hoffmann La Roche Ltd.
○ Eli Lilly And Company
○ Merck & Co., Inc.
○ Teva Pharmaceutical Industries Ltd.
○ Celltrion Healthcare Co., Ltd.
○ samsung bioepis
○ Bristol Myers Squibb Company

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：胃がん市場、疾患タイプ別
第5章：胃がん市場、治療タイプ別
第6章：胃がん市場、薬剤クラス別
第7章：胃がん市場、投与経路別
第8章：胃がん市場、流通チャネル別
第9章：胃がん市場、地域別
第10章：競争状況
第11章：企業情報

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Average Selling Price
3.7. Brand Share Analysis
3.8. Key Regulation Analysis
3.9. Market Share Analysis
3.10. Patent Landscape
3.11. Regulatory Guidelines
3.12. Value Chain Analysis
CHAPTER 4: GASTRIC CANCER MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Adenocarcinoma
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Lymphoma
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Gastrointestinal Stromal Tumor
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Carcinoid Tumor
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: GASTRIC CANCER MARKET, BY TREATMENT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Immunotherapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Targeted Therapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Chemotherapy
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Radiation Therapy and Surgery
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK
6.1. Overview
6.1.1. Market size and forecast
6.2. PD-1/PD-L1 Inhibitors
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. HER2 Antagonists
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. VEGFR2 Antagonists
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.1.1. Market size and forecast
7.2. Oral
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Injectable
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
CHAPTER 8: GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL
8.1. Overview
8.1.1. Market size and forecast
8.2. Hospital Pharmacies
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by region
8.2.3. Market share analysis by country
8.3. Specialty and Retail Pharmacies
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by region
8.3.3. Market share analysis by country
8.4. Others
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by region
8.4.3. Market share analysis by country
CHAPTER 9: GASTRIC CANCER MARKET, BY REGION
9.1. Overview
9.1.1. Market size and forecast By Region
9.2. North America
9.2.1. Key trends and opportunities
9.2.2. Market size and forecast, by Disease Type
9.2.3. Market size and forecast, by Treatment Type
9.2.4. Market size and forecast, by Drug Class Outlook
9.2.5. Market size and forecast, by Route of Administration
9.2.6. Market size and forecast, by Distribution Channel
9.2.7. Market size and forecast, by country
9.2.7.1. U.S.
9.2.7.1.1. Key market trends, growth factors and opportunities
9.2.7.1.2. Market size and forecast, by Disease Type
9.2.7.1.3. Market size and forecast, by Treatment Type
9.2.7.1.4. Market size and forecast, by Drug Class Outlook
9.2.7.1.5. Market size and forecast, by Route of Administration
9.2.7.1.6. Market size and forecast, by Distribution Channel
9.2.7.2. Canada
9.2.7.2.1. Key market trends, growth factors and opportunities
9.2.7.2.2. Market size and forecast, by Disease Type
9.2.7.2.3. Market size and forecast, by Treatment Type
9.2.7.2.4. Market size and forecast, by Drug Class Outlook
9.2.7.2.5. Market size and forecast, by Route of Administration
9.2.7.2.6. Market size and forecast, by Distribution Channel
9.2.7.3. Mexico
9.2.7.3.1. Key market trends, growth factors and opportunities
9.2.7.3.2. Market size and forecast, by Disease Type
9.2.7.3.3. Market size and forecast, by Treatment Type
9.2.7.3.4. Market size and forecast, by Drug Class Outlook
9.2.7.3.5. Market size and forecast, by Route of Administration
9.2.7.3.6. Market size and forecast, by Distribution Channel
9.3. Europe
9.3.1. Key trends and opportunities
9.3.2. Market size and forecast, by Disease Type
9.3.3. Market size and forecast, by Treatment Type
9.3.4. Market size and forecast, by Drug Class Outlook
9.3.5. Market size and forecast, by Route of Administration
9.3.6. Market size and forecast, by Distribution Channel
9.3.7. Market size and forecast, by country
9.3.7.1. Germany
9.3.7.1.1. Key market trends, growth factors and opportunities
9.3.7.1.2. Market size and forecast, by Disease Type
9.3.7.1.3. Market size and forecast, by Treatment Type
9.3.7.1.4. Market size and forecast, by Drug Class Outlook
9.3.7.1.5. Market size and forecast, by Route of Administration
9.3.7.1.6. Market size and forecast, by Distribution Channel
9.3.7.2. UK
9.3.7.2.1. Key market trends, growth factors and opportunities
9.3.7.2.2. Market size and forecast, by Disease Type
9.3.7.2.3. Market size and forecast, by Treatment Type
9.3.7.2.4. Market size and forecast, by Drug Class Outlook
9.3.7.2.5. Market size and forecast, by Route of Administration
9.3.7.2.6. Market size and forecast, by Distribution Channel
9.3.7.3. France
9.3.7.3.1. Key market trends, growth factors and opportunities
9.3.7.3.2. Market size and forecast, by Disease Type
9.3.7.3.3. Market size and forecast, by Treatment Type
9.3.7.3.4. Market size and forecast, by Drug Class Outlook
9.3.7.3.5. Market size and forecast, by Route of Administration
9.3.7.3.6. Market size and forecast, by Distribution Channel
9.3.7.4. Spain
9.3.7.4.1. Key market trends, growth factors and opportunities
9.3.7.4.2. Market size and forecast, by Disease Type
9.3.7.4.3. Market size and forecast, by Treatment Type
9.3.7.4.4. Market size and forecast, by Drug Class Outlook
9.3.7.4.5. Market size and forecast, by Route of Administration
9.3.7.4.6. Market size and forecast, by Distribution Channel
9.3.7.5. Italy
9.3.7.5.1. Key market trends, growth factors and opportunities
9.3.7.5.2. Market size and forecast, by Disease Type
9.3.7.5.3. Market size and forecast, by Treatment Type
9.3.7.5.4. Market size and forecast, by Drug Class Outlook
9.3.7.5.5. Market size and forecast, by Route of Administration
9.3.7.5.6. Market size and forecast, by Distribution Channel
9.3.7.6. Rest of Europe
9.3.7.6.1. Key market trends, growth factors and opportunities
9.3.7.6.2. Market size and forecast, by Disease Type
9.3.7.6.3. Market size and forecast, by Treatment Type
9.3.7.6.4. Market size and forecast, by Drug Class Outlook
9.3.7.6.5. Market size and forecast, by Route of Administration
9.3.7.6.6. Market size and forecast, by Distribution Channel
9.4. Asia-Pacific
9.4.1. Key trends and opportunities
9.4.2. Market size and forecast, by Disease Type
9.4.3. Market size and forecast, by Treatment Type
9.4.4. Market size and forecast, by Drug Class Outlook
9.4.5. Market size and forecast, by Route of Administration
9.4.6. Market size and forecast, by Distribution Channel
9.4.7. Market size and forecast, by country
9.4.7.1. China
9.4.7.1.1. Key market trends, growth factors and opportunities
9.4.7.1.2. Market size and forecast, by Disease Type
9.4.7.1.3. Market size and forecast, by Treatment Type
9.4.7.1.4. Market size and forecast, by Drug Class Outlook
9.4.7.1.5. Market size and forecast, by Route of Administration
9.4.7.1.6. Market size and forecast, by Distribution Channel
9.4.7.2. Japan
9.4.7.2.1. Key market trends, growth factors and opportunities
9.4.7.2.2. Market size and forecast, by Disease Type
9.4.7.2.3. Market size and forecast, by Treatment Type
9.4.7.2.4. Market size and forecast, by Drug Class Outlook
9.4.7.2.5. Market size and forecast, by Route of Administration
9.4.7.2.6. Market size and forecast, by Distribution Channel
9.4.7.3. India
9.4.7.3.1. Key market trends, growth factors and opportunities
9.4.7.3.2. Market size and forecast, by Disease Type
9.4.7.3.3. Market size and forecast, by Treatment Type
9.4.7.3.4. Market size and forecast, by Drug Class Outlook
9.4.7.3.5. Market size and forecast, by Route of Administration
9.4.7.3.6. Market size and forecast, by Distribution Channel
9.4.7.4. South Korea
9.4.7.4.1. Key market trends, growth factors and opportunities
9.4.7.4.2. Market size and forecast, by Disease Type
9.4.7.4.3. Market size and forecast, by Treatment Type
9.4.7.4.4. Market size and forecast, by Drug Class Outlook
9.4.7.4.5. Market size and forecast, by Route of Administration
9.4.7.4.6. Market size and forecast, by Distribution Channel
9.4.7.5. Australia
9.4.7.5.1. Key market trends, growth factors and opportunities
9.4.7.5.2. Market size and forecast, by Disease Type
9.4.7.5.3. Market size and forecast, by Treatment Type
9.4.7.5.4. Market size and forecast, by Drug Class Outlook
9.4.7.5.5. Market size and forecast, by Route of Administration
9.4.7.5.6. Market size and forecast, by Distribution Channel
9.4.7.6. Rest of Asia-Pacific
9.4.7.6.1. Key market trends, growth factors and opportunities
9.4.7.6.2. Market size and forecast, by Disease Type
9.4.7.6.3. Market size and forecast, by Treatment Type
9.4.7.6.4. Market size and forecast, by Drug Class Outlook
9.4.7.6.5. Market size and forecast, by Route of Administration
9.4.7.6.6. Market size and forecast, by Distribution Channel
9.5. LAMEA
9.5.1. Key trends and opportunities
9.5.2. Market size and forecast, by Disease Type
9.5.3. Market size and forecast, by Treatment Type
9.5.4. Market size and forecast, by Drug Class Outlook
9.5.5. Market size and forecast, by Route of Administration
9.5.6. Market size and forecast, by Distribution Channel
9.5.7. Market size and forecast, by country
9.5.7.1. Brazil
9.5.7.1.1. Key market trends, growth factors and opportunities
9.5.7.1.2. Market size and forecast, by Disease Type
9.5.7.1.3. Market size and forecast, by Treatment Type
9.5.7.1.4. Market size and forecast, by Drug Class Outlook
9.5.7.1.5. Market size and forecast, by Route of Administration
9.5.7.1.6. Market size and forecast, by Distribution Channel
9.5.7.2. United Arab Emirates
9.5.7.2.1. Key market trends, growth factors and opportunities
9.5.7.2.2. Market size and forecast, by Disease Type
9.5.7.2.3. Market size and forecast, by Treatment Type
9.5.7.2.4. Market size and forecast, by Drug Class Outlook
9.5.7.2.5. Market size and forecast, by Route of Administration
9.5.7.2.6. Market size and forecast, by Distribution Channel
9.5.7.3. Saudi Arabia
9.5.7.3.1. Key market trends, growth factors and opportunities
9.5.7.3.2. Market size and forecast, by Disease Type
9.5.7.3.3. Market size and forecast, by Treatment Type
9.5.7.3.4. Market size and forecast, by Drug Class Outlook
9.5.7.3.5. Market size and forecast, by Route of Administration
9.5.7.3.6. Market size and forecast, by Distribution Channel
9.5.7.4. South Africa
9.5.7.4.1. Key market trends, growth factors and opportunities
9.5.7.4.2. Market size and forecast, by Disease Type
9.5.7.4.3. Market size and forecast, by Treatment Type
9.5.7.4.4. Market size and forecast, by Drug Class Outlook
9.5.7.4.5. Market size and forecast, by Route of Administration
9.5.7.4.6. Market size and forecast, by Distribution Channel
9.5.7.5. Rest of LAMEA
9.5.7.5.1. Key market trends, growth factors and opportunities
9.5.7.5.2. Market size and forecast, by Disease Type
9.5.7.5.3. Market size and forecast, by Treatment Type
9.5.7.5.4. Market size and forecast, by Drug Class Outlook
9.5.7.5.5. Market size and forecast, by Route of Administration
9.5.7.5.6. Market size and forecast, by Distribution Channel
CHAPTER 10: COMPETITIVE LANDSCAPE
10.1. Introduction
10.2. Top winning strategies
10.3. Product Mapping of Top 10 Player
10.4. Competitive Dashboard
10.5. Competitive Heatmap
10.6. Top player positioning, 2021
CHAPTER 11: COMPANY PROFILES
11.1. Novartis AG
11.1.1. Company overview
11.1.2. Key Executives
11.1.3. Company snapshot
11.2. Pfizer, Inc.
11.2.1. Company overview
11.2.2. Key Executives
11.2.3. Company snapshot
11.3. Mylan N.V.
11.3.1. Company overview
11.3.2. Key Executives
11.3.3. Company snapshot
11.4. F. Hoffmann La Roche Ltd.
11.4.1. Company overview
11.4.2. Key Executives
11.4.3. Company snapshot
11.5. Eli Lilly And Company
11.5.1. Company overview
11.5.2. Key Executives
11.5.3. Company snapshot
11.6. Merck & Co., Inc.
11.6.1. Company overview
11.6.2. Key Executives
11.6.3. Company snapshot
11.7. Teva Pharmaceutical Industries Ltd.
11.7.1. Company overview
11.7.2. Key Executives
11.7.3. Company snapshot
11.8. Celltrion Healthcare Co., Ltd.
11.8.1. Company overview
11.8.2. Key Executives
11.8.3. Company snapshot
11.9. samsung bioepis
11.9.1. Company overview
11.9.2. Key Executives
11.9.3. Company snapshot
11.10. Bristol Myers Squibb Company
11.10.1. Company overview
11.10.2. Key Executives
11.10.3. Company snapshot

LIST OF TABLES
TABLE 01. GLOBAL GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 02. GASTRIC CANCER MARKET FOR ADENOCARCINOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 03. GASTRIC CANCER MARKET FOR LYMPHOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 04. GASTRIC CANCER MARKET FOR GASTROINTESTINAL STROMAL TUMOR, BY REGION, 2021-2031 ($MILLION)
TABLE 05. GASTRIC CANCER MARKET FOR CARCINOID TUMOR, BY REGION, 2021-2031 ($MILLION)
TABLE 06. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 07. GLOBAL GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 08. GASTRIC CANCER MARKET FOR IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 09. GASTRIC CANCER MARKET FOR TARGETED THERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 10. GASTRIC CANCER MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 11. GASTRIC CANCER MARKET FOR RADIATION THERAPY AND SURGERY, BY REGION, 2021-2031 ($MILLION)
TABLE 12. GLOBAL GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 13. GASTRIC CANCER MARKET FOR PD-1/PD-L1 INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. GASTRIC CANCER MARKET FOR HER2 ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
TABLE 15. GASTRIC CANCER MARKET FOR VEGFR2 ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
TABLE 16. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 17. GLOBAL GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 18. GASTRIC CANCER MARKET FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 19. GASTRIC CANCER MARKET FOR INJECTABLE, BY REGION, 2021-2031 ($MILLION)
TABLE 20. GLOBAL GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 21. GASTRIC CANCER MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 22. GASTRIC CANCER MARKET FOR SPECIALTY AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 23. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 24. GASTRIC CANCER MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 25. NORTH AMERICA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. U.S. GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 32. U.S. GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 33. U.S. GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 34. U.S. GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 35. U.S. GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 36. CANADA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 37. CANADA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 38. CANADA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 39. CANADA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 40. CANADA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. MEXICO GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 42. MEXICO GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 43. MEXICO GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 44. MEXICO GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 45. MEXICO GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 46. EUROPE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 47. EUROPE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 48. EUROPE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 49. EUROPE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 50. EUROPE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 51. EUROPE GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 52. GERMANY GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 53. GERMANY GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 54. GERMANY GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 55. GERMANY GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 56. GERMANY GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 57. UK GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 58. UK GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 59. UK GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 60. UK GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 61. UK GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 62. FRANCE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 63. FRANCE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 64. FRANCE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 65. FRANCE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 66. FRANCE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. SPAIN GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 68. SPAIN GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 69. SPAIN GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 70. SPAIN GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 71. SPAIN GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 72. ITALY GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 73. ITALY GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 74. ITALY GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 75. ITALY GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 76. ITALY GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 77. REST OF EUROPE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 78. REST OF EUROPE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 79. REST OF EUROPE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 80. REST OF EUROPE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 81. REST OF EUROPE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 82. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 83. ASIA-PACIFIC GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 84. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 85. ASIA-PACIFIC GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 86. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. ASIA-PACIFIC GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 88. CHINA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 89. CHINA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 90. CHINA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 91. CHINA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 92. CHINA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 93. JAPAN GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 94. JAPAN GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 95. JAPAN GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 96. JAPAN GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 97. JAPAN GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. INDIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 99. INDIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 100. INDIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 101. INDIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 102. INDIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 103. SOUTH KOREA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 104. SOUTH KOREA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 105. SOUTH KOREA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 106. SOUTH KOREA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 107. SOUTH KOREA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 108. AUSTRALIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 109. AUSTRALIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 110. AUSTRALIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 111. AUSTRALIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 112. AUSTRALIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 113. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 114. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 115. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 116. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 117. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 118. LAMEA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 119. LAMEA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 120. LAMEA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 121. LAMEA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 122. LAMEA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 123. LAMEA GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 124. BRAZIL GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 125. BRAZIL GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 126. BRAZIL GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 127. BRAZIL GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 128. BRAZIL GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 129. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 130. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 131. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 132. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 133. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 134. SAUDI ARABIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 135. SAUDI ARABIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 136. SAUDI ARABIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 137. SAUDI ARABIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 138. SAUDI ARABIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 139. SOUTH AFRICA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 140. SOUTH AFRICA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 141. SOUTH AFRICA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 142. SOUTH AFRICA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 143. SOUTH AFRICA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 144. REST OF LAMEA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 145. REST OF LAMEA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
TABLE 146. REST OF LAMEA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
TABLE 147. REST OF LAMEA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 148. REST OF LAMEA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 149. NOVARTIS AG: KEY EXECUTIVES
TABLE 150. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 151. PFIZER, INC.: KEY EXECUTIVES
TABLE 152. PFIZER, INC.: COMPANY SNAPSHOT
TABLE 153. MYLAN N.V.: KEY EXECUTIVES
TABLE 154. MYLAN N.V.: COMPANY SNAPSHOT
TABLE 155. F. HOFFMANN LA ROCHE LTD.: KEY EXECUTIVES
TABLE 156. F. HOFFMANN LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 157. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 158. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 159. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 160. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 161. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 162. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 163. CELLTRION HEALTHCARE CO., LTD.: KEY EXECUTIVES
TABLE 164. CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT
TABLE 165. SAMSUNG BIOEPIS: KEY EXECUTIVES
TABLE 166. SAMSUNG BIOEPIS: COMPANY SNAPSHOT
TABLE 167. BRISTOL MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 168. BRISTOL MYERS SQUIBB COMPANY: COMPANY SNAPSHOT

★調査レポート[世界の胃がん市場2021年-2031年：疾患種類別（腺がん、リンパ腫、消化管間質腫瘍、カルチノイド腫瘍、その他）、治療種類別（免疫療法、標的療法、化学療法、放射線療法＆外科）、薬剤クラス別（PD-1/PD-L1阻害剤、HER2アンタゴニスト、VEGFR2アンタゴニスト、その他）、投与経路別（経口、注射剤）、流通チャネル別（病院薬局、専門薬局＆小売薬局、その他）] (コード：ALD23SEP129)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の胃がん市場2021年-2031年：疾患種類別（腺がん、リンパ腫、消化管間質腫瘍、カルチノイド腫瘍、その他）、治療種類別（免疫療法、標的療法、化学療法、放射線療法＆外科）、薬剤クラス別（PD-1/PD-L1阻害剤、HER2アンタゴニスト、VEGFR2アンタゴニスト、その他）、投与経路別（経口、注射剤）、流通チャネル別（病院薬局、専門薬局＆小売薬局、その他）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のリンパ腫治療薬市場2023年-2032年：疾患種類別（ホジキンリンパ腫、非ホジキンリンパ腫）、治療種類別（免疫療法、化学療法、標的療法、放射線療法）、投与経路別（経口経路、注射）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 世界の非ホジキンリンパ腫治療薬市場2022-2029：治療種類別（免疫療法、化学療法、標的療法、その他）、疾患種類別、流通チャネル別、地域別
  • 世界の肺がん治療市場（2022-2031）：治療種類別（手術、放射線療法、標的療法、免疫療法、化学療法、その他）
  • 世界の白血病治療薬市場2021年-2031年：種類別（急性リンパ球性白血病、急性骨髄性白血病、慢性リンパ球性白血病、慢性骨髄性白血病、その他）、薬剤クラス別（化学療法、標的療法、免疫療法）、流通チャネル別（病院内薬剤、ドラッグストア＆小売薬局、オンラインプロバイダー）
  • 動物における腫瘍のグローバル市場2023～2033：放射線療法、化学療法、併用療法、免疫療法、標的療法
  • 世界の上咽頭がん治療市場2023-2031：治療種類別（放射線療法、化学療法、免疫療法、その他）、エンドユーザー別（病院、専門クリニック、その他）
  • 世界の肝臓転移治療市場2023-2030：治療種類別（化学療法、免疫療法、標的療法）、原発性がん別（大腸がん、乳がん）、流通チャネル別、地域別
  • 世界の急性リンパ性白血病（ALL）市場2022-2031：種類別（B細胞性急性リンパ性白血病（ALL）、T細胞性急性リンパ性白血病（ALL））、治療法別（化学療法、放射線療法、骨髄移植、標的療法、免疫療法）

    • ◆H&Iグローバルリサーチのお客様（例）◆